• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体外和体内评估奈玛特韦穿透脑脊液、中枢神经系统细胞、组织和外周血单核细胞的能力。

In-vitro and in-vivo assessment of nirmatrelvir penetration into CSF, central nervous system cells, tissues, and peripheral blood mononuclear cells.

机构信息

Antiviral Pharmacology Laboratory, College of Pharmacy, University of Nebraska Medical Center, 986145 Nebraska Medical Center, Omaha, NE, 68198-6145, USA.

Department of Pediatrics, Division of Infectious Diseases, University of Southern California, Children's Hospital Los Angeles, Los Angeles, CA, USA.

出版信息

Sci Rep. 2024 May 10;14(1):10709. doi: 10.1038/s41598-024-60935-5.

DOI:10.1038/s41598-024-60935-5
PMID:38729980
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11087525/
Abstract

Three years after SARS-CoV-2 emerged as a global infectious threat, the virus has become endemic. The neurological complications such as depression, anxiety, and other CNS complications after COVID-19 disease are increasing. The brain, and CSF have been shown as viral reservoirs for SARS-CoV-2, yielding a potential hypothesis for CNS effects. Thus, we investigated the CNS pharmacology of orally dosed nirmatrelvir/ritonavir (NMR/RTV). Using both an in vitro and an in vivo rodent model, we investigated CNS penetration and potential pharmacodynamic activity of NMR. Through pharmacokinetic modeling, we estimated the median CSF penetration of NMR to be low at 18.11% of plasma with very low accumulation in rodent brain tissue. Based on the multiples of the 90% maximal effective concentration (EC) for SARS-CoV-2, NMR concentrations in the CSF and brain do not achieve an exposure level similar to that of plasma. A median of only 16% of all the predicted CSF concentrations in rats were > 3xEC (unadjusted for protein binding). This may have implications for viral persistence and neurologic post-acute sequelae of COVID-19 if increased NMR penetration in the CNS leads to decreased CNS viral loads and decreased CNS inflammation.

摘要

SARS-CoV-2 作为一种全球性传染病威胁出现三年后,该病毒已成为地方性疾病。COVID-19 疾病后出现的抑郁、焦虑和其他中枢神经系统并发症等神经并发症正在增加。大脑和脑脊液已被证明是 SARS-CoV-2 的病毒储存库,为中枢神经系统的影响提供了一个潜在的假设。因此,我们研究了口服尼马曲韦/利托那韦(NMR/RTV)的中枢神经系统药理学。我们使用体外和体内啮齿动物模型研究了 NMR 的中枢神经系统渗透和潜在的药效学活性。通过药代动力学建模,我们估计 NMR 在脑脊液中的中位数渗透率为血浆的 18.11%,在啮齿动物脑组织中的蓄积非常低。基于 SARS-CoV-2 的 90%最大有效浓度(EC)的倍数,NMR 在脑脊液和大脑中的浓度未达到与血浆相似的暴露水平。在大鼠中,只有中位数 16%的所有预测的脑脊液浓度>3xEC(未考虑蛋白结合)。如果中枢神经系统中 NMR 渗透增加导致中枢神经系统病毒载量降低和中枢神经系统炎症减少,这可能对 COVID-19 的病毒持续存在和神经后急性后遗症产生影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4b6/11087525/e693ffc86bfa/41598_2024_60935_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4b6/11087525/5dcff8dcdd58/41598_2024_60935_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4b6/11087525/d8bf8b028aab/41598_2024_60935_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4b6/11087525/e693ffc86bfa/41598_2024_60935_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4b6/11087525/5dcff8dcdd58/41598_2024_60935_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4b6/11087525/d8bf8b028aab/41598_2024_60935_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4b6/11087525/e693ffc86bfa/41598_2024_60935_Fig3_HTML.jpg

相似文献

1
In-vitro and in-vivo assessment of nirmatrelvir penetration into CSF, central nervous system cells, tissues, and peripheral blood mononuclear cells.体外和体内评估奈玛特韦穿透脑脊液、中枢神经系统细胞、组织和外周血单核细胞的能力。
Sci Rep. 2024 May 10;14(1):10709. doi: 10.1038/s41598-024-60935-5.
2
Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.创新的随机I期研究及给药方案选择,以加速并为奈玛特韦的关键COVID-19试验提供信息。
Clin Pharmacol Ther. 2022 Jul;112(1):101-111. doi: 10.1002/cpt.2603. Epub 2022 May 4.
3
Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.新型冠状病毒病 2019 经奈玛特韦/利托那韦治疗后出现症状反弹的临床、病毒学和免疫学评估。
Clin Infect Dis. 2023 Feb 18;76(4):573-581. doi: 10.1093/cid/ciac663.
4
Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants.用于治疗新冠肺炎的奈玛特韦/利托那韦联合疗法的临床前发现与开发以及从新冠病毒变异株中吸取的经验教训。
Expert Opin Drug Discov. 2023 Jul-Dec;18(12):1301-1311. doi: 10.1080/17460441.2023.2248879. Epub 2023 Aug 23.
5
CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series.COVID-19 伴有神经系统症状患者的脑脊液生物标志物:病例系列研究。
Neurology. 2021 Jan 12;96(2):e294-e300. doi: 10.1212/WNL.0000000000010977. Epub 2020 Oct 1.
6
Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.奥密克戎变异株流行期间,未住院的 2 型糖尿病合并 SARS-CoV-2 感染患者接受莫努匹韦或奈玛特韦/利托那韦治疗后的全因住院和死亡分析。
JAMA Netw Open. 2023 May 1;6(5):e2314393. doi: 10.1001/jamanetworkopen.2023.14393.
7
A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir.奈玛特韦/利托那韦的临床药代动力学、药效学和药物相互作用的全面综述。
Clin Pharmacokinet. 2024 Jan;63(1):27-42. doi: 10.1007/s40262-023-01339-y. Epub 2024 Jan 4.
8
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦片/利托那韦片组合包装用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2.
9
Evidence of central nervous system infection and neuroinvasive routes, as well as neurological involvement, in the lethality of SARS-CoV-2 infection.SARS-CoV-2 感染致死性中的中枢神经系统感染和神经侵袭途径以及神经受累的证据。
J Med Virol. 2021 Mar;93(3):1304-1313. doi: 10.1002/jmv.26570. Epub 2020 Oct 14.
10
Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2.基于生理的药代动力学建模以预测洛匹那韦和利托那韦联合使用对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的临床疗效
Clin Pharmacol Ther. 2020 Dec;108(6):1176-1184. doi: 10.1002/cpt.2014. Epub 2020 Oct 6.

引用本文的文献

1
Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M inhibitors with potent in vivo efficacy.基于结构发现具有高生物利用度、共价、广谱冠状病毒M抑制剂并具有强大的体内疗效。
Sci Adv. 2025 Apr 25;11(17):eadt7836. doi: 10.1126/sciadv.adt7836. Epub 2025 Apr 23.

本文引用的文献

1
Neuroinvasion and anosmia are independent phenomena upon infection with SARS-CoV-2 and its variants.神经侵袭和嗅觉丧失是感染 SARS-CoV-2 及其变体时独立的现象。
Nat Commun. 2023 Jul 26;14(1):4485. doi: 10.1038/s41467-023-40228-7.
2
The 27th Scientific Conference of the Society on NeuroImmune Pharmacology: New Delhi, India, March 15-18, 2023.神经免疫药理学学会第27届科学会议:印度新德里,2023年3月15日至18日。
NeuroImmune Pharm Ther. 2023 Apr 10;2(2):187-244. doi: 10.1515/nipt-2023-0006. eCollection 2023 Jun.
3
Quantification of nine antiretroviral drugs in cerebrospinal fluid: An approach to overcome sample collection tube adsorption.
定量检测脑脊液中的九种抗逆转录病毒药物:克服样本采集管吸附的方法。
J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Jul 1;1227:123810. doi: 10.1016/j.jchromb.2023.123810. Epub 2023 Jun 30.
4
ACE-2, TMPRSS2, and Neuropilin-1 Receptor Expression on Human Brain Astrocytes and Pericytes and SARS-CoV-2 Infection Kinetics.人脑星形胶质细胞和周细胞上的 ACE-2、TMPRSS2 和 Neuropilin-1 受体表达及 SARS-CoV-2 感染动力学。
Int J Mol Sci. 2023 May 11;24(10):8622. doi: 10.3390/ijms24108622.
5
A novel 4-cell in-vitro blood-brain barrier model and its characterization by confocal microscopy and TEER measurement.一种新型的四细胞体外血脑屏障模型及其通过共聚焦显微镜和 TEER 测量的特征描述。
J Neurosci Methods. 2023 May 15;392:109867. doi: 10.1016/j.jneumeth.2023.109867. Epub 2023 Apr 26.
6
Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?帕克洛维德(奈玛特韦/利托那韦):新冠治疗的新方法?
Biomed Pharmacother. 2023 Jun;162:114367. doi: 10.1016/j.biopha.2023.114367. Epub 2023 Feb 6.
7
Alteration of the blood-brain barrier by COVID-19 and its implication in the permeation of drugs into the brain.新冠病毒对血脑屏障的改变及其对药物渗入大脑的影响。
Front Cell Neurosci. 2023 Mar 14;17:1125109. doi: 10.3389/fncel.2023.1125109. eCollection 2023.
8
Population Pharmacokinetic Analysis of Rifampicin in Plasma, Cerebrospinal Fluid, and Brain Extracellular Fluid in South African Children with Tuberculous Meningitis.南非结核性脑膜炎儿童血浆、脑脊液和脑细胞外液中利福平的群体药代动力学分析。
Antimicrob Agents Chemother. 2023 Mar 16;67(3):e0147422. doi: 10.1128/aac.01474-22. Epub 2023 Feb 23.
9
Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir.在实体器官移植受者中,利托那韦增强的 SARS-CoV-2 蛋白酶抑制剂的药物相互作用:洛匹那韦-利托那韦初步使用的经验。
Clin Microbiol Infect. 2023 May;29(5):655.e1-655.e4. doi: 10.1016/j.cmi.2023.01.002. Epub 2023 Jan 11.
10
Population Pharmacokinetics and Dosing Regimen Optimization of Linezolid in Cerebrospinal Fluid and Plasma of Post-operative Neurosurgical Patients.术后神经外科患者脑脊液和血浆中利奈唑胺的群体药代动力学和给药方案优化。
J Pharm Sci. 2023 Mar;112(3):884-892. doi: 10.1016/j.xphs.2022.12.016. Epub 2022 Dec 22.